Evaluation of the central corneal thickness, retinal thickness and intraocular pressure in patients with euthyroid Hashimoto’s thyroiditis

Fatma Neslihan Cuhacı Seyrek 1, Hüsnüye Başer 1, Nagihan Uğurlu 2, Fatma Yülek 2, Reyhan Ersoy 1, Nurullah Çağil 2, Bekir Çakır 1
(1) Ankara Yıldırım Beyazıt University, Faculty of Medicine, Endocrinology and Metabolism, Ankara, Turkey
(2) Ankara Yıldırım Beyazıt University, Faculty of Medicine, Ophthalmology, Ankara, Turkey

Introduction

Hashimoto’s thyroiditis (HT), which was first described over a century ago is defined as a chronic inflammatory condition of the thyroid gland. It is the most common cause of hypothyroidism and considered the most common autoimmune disease and a common endocrine disorder (1-3). Combination of clinical features, the presence of serum antibodies against thyroid antigens such as thyroid peroxidase (TPO) and thyroglobulin (TG), and ultrasonography findings are the identifiers of the HT (4). The sonographic features of HT include; a diffusely enlarged thyroid gland, coarse parenchymal echogenicity, more hypoechoic images than normal, often hypervascular on color Doppler ultrasonography, as well as the presence of a micronodular pattern, which is a strong indicator (5-6).

The best serological marker to identify the HT is thought to be the circulating antibodies against TPO (anti-TPO), which are found in about 95% of HT patients but rarely in healthy controls (4). Antibodies to TG (anti-TG) are less sensitive (positive in only 60–80% of HT patients) and less specific than TPO antibodies (4). There are some groups of patients who are in a euthyroid state but have elevated thyroid antibody levels (7).

The eye is one of the organs which have predisposition of the impacts of various systemic disorders (8) such as hypothyroidism and hyperthyroidism. Thyroid hormones take an essential role in the neural development of the eye, particularly for normal development of the retina and the success of color vision (8). It also organizes the intrinsic mechanisms to handle the retinal cytoarchitecture and layering (9). It has been reported that acquired deficiency of thyroid hormones affects the intraocular pressure (IOP), as well as orbitopathies, such as periorbital edema and chemosis associated to myxedema (10). Centanni et al. (11) showed a reversible increase in IOP even in subclinical hypothyroidism; this finding brought about the question of whether some microscopic findings precede the macroscopic findings of hypothyroidism. Increased IOP and visual field defects can actually be seen in cases of severe Graves ophthalmopathy (12). The effects of thyroid disorders on the central corneal thickness (CCT) are not well defined in the literature. Central corneal thickness has been demonstrated to play a role in the interpretation of IOP (12).

ABSTRACT

Aims: There are few data concerning the effects of thyroid disorders on intraocular pressure (IOP), central corneal thickness (CCT) and retinal thickness (RT) and to our knowledge no data have been reported in Hashimoto’s thyroiditis (HT). In this study we aimed to evaluate the alterations in IOP, CCT and RT in patients with euthyroid HT.

Methods: In this cross-sectional study we examined IOP, CCT and RT in patients with euthyroid HT and age and gender matched controls.

Results: We evaluated 80 eyes of 40 patients with euthyroid HT and 96 eyes of 48 controls. Serum sensitive thyroid stimulating hormone (sTSH) (2.10±1.04 vs 1.92±1.23 uIU/ml), free triiodothyronine (fT3) (3.19±0.43 vs 3.14±0.34 pg/ml), and free tetraiodothyronine (fT4) (1.20±0.14 vs 1.18±0.13 ng/dl) levels were similar between the two groups. No statistically significant difference was observed in mean RT (266.93± 26.46 vs 275.35± 38.81 µm), CCT (533.68±29.28 vs 540.06±29.13 µm), or IOP (13.98±2.42 vs 14.32±2.62 mmHg) between HT patients and controls. In the HT group Anti-TPO was negatively correlated with mean RT (r = −0.227, p = 0.033).

Conclusions: We have found no differences in CCT, RT and IOP between euthyroid HT patients and controls. In the present study, however there was a negative correlation between the anti-TPO levels and RT.
There are few data regarding the effects of hypo- and hyperthyroidism on CCT and IOP, and to our knowledge, there is no reported data in patients with euthyroid HT. The aim of our study was to evaluate the alterations in IOP, CCT and retinal thickness (RT) in patients with euthyroid HT as to whether or not it is necessary to assess the need for follow-up in these patients from an ophthalmological point of view.

Methods

Patients

This cross-sectional study was conducted in 80 eyes of 40 patients with euthyroid HT and 96 eyes of 48 healthy subjects as controls. The diagnosis of HT was based on positive anti-TPO and anti-TG antibodies and sonographic features of the thyroid. The patients included were all euthyroid in both clinical and laboratory tests (free triiodothyronine (FT3), free thyroxine (FT4) levels and sensitive thyroid stimulating hormone (sTSH) levels were within the normal range) and had positive anti-TPO and anti-TG antibodies and moderate-to-severe parenchymal hypoechogenicity (7,13), and a micronodular pattern (6) by thyroid ultrasound. The control group consisted of healthy individuals with no history of thyroid disease.

Exclusion criteria were patients with systemic diseases (e.g., diabetes mellitus, hypertension, chronic renal failure, or chronic hepatic failure), patients with chronic ocular diseases (e.g., refraction defects, glaucoma, uveitis, keratitis, dry eye syndrome, or conjunctivitis), those using contact lenses, those with previous optic nerve damage, and those who had undergone laser treatment or systemic or topical corticosteroid use, immunosuppressive therapy, intravitreal injections to the eyes, ocular surgery, or trauma. Patients under 18 years old and those unwilling to participate were also excluded.

The study was approved by the local ethics board. Informed consent was obtained from each participant. The study protocol followed the tenets of the 1964 Declaration of Helsinki.

Laboratory tests

Levels of sTSH, FT3, FT4, and thyroid autoantibodies (anti-TPO and anti-TG) were measured in all patients using chemiluminescence methods (Immulite 2000; Diagnostic Products Corporation, Los Angeles, CA and UniCel DxI 800; Beckman Coulter, Brea, CA). The normal ranges for sTSH, FT3, FT4, anti-TPO, and anti-TG were 0.27–4.2 μIU/mL, 1.8–4.6 pg/mL, 0.9–1.7 ng/dL, 0-34 IU/ml, and 0-115 IU/ml, respectively.

An Esaote color Doppler ultrasound (US) system (Model 796FDII; MAG Technology Co. Ltd., Yung-Ho City, Taipei, Taiwan) and a standard US system with a superficial probe (Model LA523 13-4, 5.5 and 12.5 MHz) were used. Chronic thyroiditis was defined when the thyroid gland was diffusely heterogeneous and/or hypoechoic with/without pseudonodules and fibrotic bands.

Statistical analysis

All statistical analyses were performed with the SPSS software (ver. 15.0; SPSS Inc., Chicago, IL, USA). Descriptive analyses are presented using means ± standard deviation (SD) for normally distributed variables, and medians and range (min-max) for non-normally distributed variables. The x² test was used to investigate differences between groups regarding categorical variables. Comparisons between groups were performed using Student’s t-test for parametric variables and the Mann–Whitney U-test for non-parametric variables. Pearson’s and Spearman’s correlation analyses were performed to assess possible associations between parametric and non-parametric variables, respectively. A p-value < 0.05 was considered to indicate statistical significance.

Results

In total, 40 patients (2 males, 38 females) with euthyroid HT, with a mean age of 41.95 ± 10.47 years and 48 (4 males, 44 females) healthy subjects, with a mean age of 43.50 ± 9.99 years, were evaluated. There was no significant difference between patients and control group with regard to age or gender (all p > 0.05). Serum sTSH, FT3, and FT4 levels were similar between the two groups. Anti-TPO and anti-TG levels of euthyroid HT patients were significantly higher than those of the controls (each p < 0.001). Demographical and biochemical data of the study group are given in Table 1. No statistically significant dif-

<table>
<thead>
<tr>
<th>Variables</th>
<th>Patients (n=40)</th>
<th>Controls (n=48)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>41.95±10.47</td>
<td>43.50±9.99</td>
<td>0.480</td>
</tr>
<tr>
<td>Female/Male</td>
<td>38/2</td>
<td>44/4</td>
<td>0.537</td>
</tr>
<tr>
<td>FT3 (pg/ml)</td>
<td>3.19±0.43</td>
<td>3.14±0.34</td>
<td>0.567</td>
</tr>
<tr>
<td>FT4 (ng/dl)</td>
<td>1.20±0.14</td>
<td>1.18±0.13</td>
<td>0.416</td>
</tr>
<tr>
<td>sTSH (uIU/ml)</td>
<td>2.10±1.04</td>
<td>1.92±1.23</td>
<td>0.475</td>
</tr>
<tr>
<td>Anti-TPO (IU/ml)</td>
<td>97.94 (35-1000)</td>
<td>8.15 (5-32.3)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Anti-TG (IU/ml)</td>
<td>178.30 (118.6-4000)</td>
<td>17.98 (10-100.40)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Mean RT (µm)</td>
<td>266.93±26.46</td>
<td>275.35±38.81</td>
<td>0.101</td>
</tr>
<tr>
<td>Mean CCT (µm)</td>
<td>533.68±29.28</td>
<td>540.06±29.13</td>
<td>0.161</td>
</tr>
<tr>
<td>Mean IOP (mmHg)</td>
<td>13.98±2.42</td>
<td>14.32±2.62</td>
<td>0.390</td>
</tr>
</tbody>
</table>

with the IOP rise in hypothyroidism were released for publica-
tion. The first reports related to IOP measurements (19,20). Several reports indicate the higher
elevated IOP (15,16). It is the second leading cause of blind-
ess in the worldwide and usually assessed with Goldmann
applanation tonometry (GAT), which is the gold standard for
IOP measurements (19,20). Several reports indicate the higher
reading, such as limbal concavity, wall stiffness, and peripher-
al corneal thickness (27). In this study we used the GAT. GAT
may be various factors affecting this small difference in IOP
outflow in hypothyroid patients (24-25). In the study of Ozturk
et al.(8), they found no significant IOP decrease with treatment
in hypothyroid patients and also no correlation between IOP
measurements and the decrease in TSH. Bahceci et al. (26)
demonstrated a significant decrease in IOP with treatment;
however, it was not correlated with changes in thyroid hormone
levels.

In patients with thyroid eye disease, Rahman et al.(27) found
an average difference of 1 mmHg between the IOP measured
with GAT and the TonoPen. The authors suggested that there
may be various factors affecting this small difference in IOP
reading, such as limbal concavity, wall stiffness, and peripher-
al corneal thickness (27). In this study we used the GAT. GAT
measurements can be influenced by several ocular properties,
such as CCT, axial length, and corneal curvature as shown in
several studies (28-29). In our study, we found no correlation
in IOP between euthyroid HT patients and the control subjects,
also no differences were found according the sTSH levels. Such
possible factors and euthyroid state may be responsible for the
unsignificant results in our study. Reagarding with the Gold-
mann equation, IOP is positively correlated with aqueous inflow
and episcleral venous pressure, and negatively correlated with
outflow facility (30). In Graves’ orbitopathy elevated episcleral
venous pressure levels were shown, and raised retrobulbar
pressure, above normal venous pressure, has been reported
as a possible cause of reduced orbital venous drainage, which
may increase the IOP (30).

Central corneal thickness is closely related with IOP (19). The
normal CCT value in the human cornea is accepted as 536
± 0.31 µm in the literature (29). In previous studies, IOP mea-
surements were corrected using the formula given by Doughty
(29). In our study, no such correction was necessary, because
the mean CCTs were similar in both groups. In Bahceci et al.
study (26) they have showed an increased IOP and CCT in

There have been conflicting results related to the effects of
thyroid hormone on CCT and IOP (14). The first reports related
with the IOP rise in hypothyroidism were released for publica-
tion in 1897 and has been associated to hypothalamic distur-
bances, either directly or by the mediation of the pituitary gland
acting on the thyroid and eye at the same time. Glaucoma has
been related at times with thyrotoxicosis and at times with myx-
edema (15). Cheng and Perkins suggested that there may be
a genetic predisposition to both conditions (15). In 1965, Mc-
Lenachan and Davies proposed that the deposition of glycos-
aminoalginic acids in the trabecular meshwork may result with a
decrease in aqueous humor outflow (16). later, Becker et al. (17)
brought out the question as to whether or not hypothyroidism
induced myxedema of the trabecular meshwork. Smith et al.
(18) suggested that vasculopathy can change the ocular blood
flow as the mechanism of the IOP rise in hypothyroidism. Gly-
cosaminoalginic deposition in the trabecular meshwork seems
to be the most noteworthy (8).

The diagnosis of glaucoma is carried out by a fundus ex-
amination and visual field testing, typically in the presence of
raised IOP (15,16). It is the second leading cause of blind-
ness in the worldwide and usually assessed with Goldmann
applanation tonometry (GAT), which is the gold standard for
IOP measurements (19,20). Several reports indicate the higher
prevalence of primary open angle glaucoma (POAG) among
hypothyroid patients; however, in contrast, other reports have
failed to support this (18,21,22,23). Smith et al. (18) determined
an IOP decrease with treatment of hypothyroidism in a patient
with POAG, and they associated the IOP rise to a reduction in
outflow in hypothyroid patients (24-25). In the study of Ozturk
et al.(8), they found no significant IOP decrease with treatment
in hypothyroid patients and also no correlation between IOP
measurements and the decrease in TSH. Bahceci et al. (26)
demonstrated a significant decrease in IOP with treatment;
however, it was not correlated with changes in thyroid hormone
levels.

Discussion
There have been conflicting results related to the effects of
thyroid hormone on CCT and IOP (14). The first reports related
with the IOP rise in hypothyroidism were released for publica-
tion in 1897 and has been associated to hypothalamic distur-
bances, either directly or by the mediation of the pituitary gland
acting on the thyroid and eye at the same time. Glaucoma has
been related at times with thyrotoxicosis and at times with myx-
edema (15). Cheng and Perkins suggested that there may be
a genetic predisposition to both conditions (15). In 1965, Mc-
Lenachan and Davies proposed that the deposition of glycos-
aminoalginic acids in the trabecular meshwork may result with a
decrease in aqueous humor outflow (16). Later, Becker et al. (17)
brought out the question as to whether or not hypothyroidism
induced myxedema of the trabecular meshwork. Smith et al.
(18) suggested that vasculopathy can change the ocular blood
flow as the mechanism of the IOP rise in hypothyroidism. Gly-
cosaminoalginic deposition in the trabecular meshwork seems
to be the most noteworthy (8).

The patient group was re-evaluated according the sTSH lev-
el. When we used a sTSH cut-off of 2.5, specifically sTSH < 2.5
(group A) versus TSH ≥ 2.5 (group B), no significant difference
was found between the groups in mean RT, CCT, or IOP (all p
> 0.05; Table 1).

Anti-TPO was negatively correlated with mean RT (r =
-0.227, p = 0.033). However, there was no significant corre-
lation between anti-TPO levels and CCT or IOP (Table 3). Also,
no significant correlation was found between anti-TG levels,
and mean RT, CCT, or IOP (all p > 0.05).

**Table 2. Comparison the patients group according the sensitive thyroid stimulating hormone level**

<table>
<thead>
<tr>
<th>Variables</th>
<th>sTSH &lt;2.5 (group A) (n=62)</th>
<th>sTSH ≥2.5 (group B) (n=26)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>RT (µm)</td>
<td>269.33±36.18</td>
<td>276.76±27.47</td>
<td>0.185</td>
</tr>
<tr>
<td>CCT (µm)</td>
<td>536.36±28.41</td>
<td>538.54±31.60</td>
<td>0.666</td>
</tr>
<tr>
<td>IOP (mmHg)</td>
<td>14.17±2.51</td>
<td>14.12±2.57</td>
<td>0.909</td>
</tr>
</tbody>
</table>

sTSH: sensitive thyroid stimulating hormone, RT: retinal thickness, CCT: central corneal thickness, IOP: intraocular pressure.

**Table 3. Correlations between thyroid function tests and retinal thickness, central corneal thickness and intraocular pressure**

<table>
<thead>
<tr>
<th>Variables</th>
<th>sTSH</th>
<th>fT3</th>
<th>ft4</th>
<th>Anti- TPO</th>
<th>Anti-TG</th>
</tr>
</thead>
<tbody>
<tr>
<td>r</td>
<td>p</td>
<td>r</td>
<td>p</td>
<td>r</td>
<td>p</td>
</tr>
<tr>
<td>Mean RT</td>
<td>0.118</td>
<td>0.274</td>
<td>0.054</td>
<td>0.616</td>
<td>0.223</td>
</tr>
<tr>
<td>Mean CCT</td>
<td>-0.085</td>
<td>0.445</td>
<td>-0.079</td>
<td>0.478</td>
<td>0.059</td>
</tr>
<tr>
<td>Mean IOP</td>
<td>-0.015</td>
<td>0.894</td>
<td>0.054</td>
<td>0.628</td>
<td>-0.096</td>
</tr>
</tbody>
</table>

hypothyroid patients and a decrease with replacement therapy. Since the corneal thickness decreased following replacement therapy they proposed that these reversible changes (both IOP and CCT decreased with treatment) may be associated to mucopolysaccharide deposition in the corneal stroma (26).

In contrast, Ozturk et al. (8) found no change in IOP or CCT with treatment in hypothyroid patients. Ozturk et al. (8) suggested that these conflicting results may be due to the different measurement methods: Bahceci et al. (26) used ultrasonic pachymetry while Ozturk et al. used a Scheimpflug camera (8). Ozturk et al. found no significant correlation between the change in TSH level and the change in CCT after the 6 months of treatment (8). Additionally, there was no significant change in the mean RT after replacement therapy, and the correlation of RT with the decrease of TSH was also not significant (8). Similarly, Atmaca et al. (14), showed no correlation between thyroid hormone and CCT or IOP. In the study of Konuk et al. (12) they evaluated CCT alterations in Graves’ disease and GO cases regarding with disease severity and hormonal status of the patients and control participants. They revealed that the CCT values of patients with Graves’ disease and patients with GO with hyperthyroid and euthyroid hormonal status showed no statistical difference among themselves or versus control participants. Also, no significant difference was found in the IOP values of the patients (12). Finally, their study revealed that neither hyperthyroidism nor severity of orbital disease affected CCT (12). Conflicting results may be attributed to an unknown period of a hypothyroid state, a younger mean age, and the lack of orbitopathy (8). Furthermore, speculations are carried out related with individuals who have prone to autoimmunity also being susceptible to thyroid disorders and glaucoma (8). In our study we found no significant differences in CCT and RT between euthyroid HT patients and control subjects and also according the sTSH levels.

The only significant result of our study was a negative correlation between anti-TPO levels and mean RT. But no correlation was found between anti-Tg levels and retinal thickness. Therefore, it is is not possible to mention a causal relationship between autoimmunity and retinal thickness. Further studies will have to be required to confirm that relation and explanation.

CONCLUSIONS: To our knowledge this is the first study to evaluate the relationship between euthyroid HT patients and RT, CCT, and IOP, and we have found no significant difference in the CCT, RT, or IOP between HT patients and control subjects. This outcome may have been due to the euthyroid state of the patients, individual differences in the patients (e.g., limbal concavity, wall stiffness, or peripheral corneal thickness), and genetic susceptibility, as mentioned above. But our study revealed a negative correlation between anti-TPO levels and RT. Therefore, we can not exactly say that it is not necessary to follow-up the euthyroid HT patients in an ophthalmological view, in contrast it may be usefull in these group of patients especially concerning with RT. To clarify this, future studies with larger sample sizes are required.


Conflict of Interest: The authors declared they do not have anything to disclose regarding conflict of interest with respect to this manuscript.

References